Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.

Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.

PMID:
31320594
2.

Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy.

Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, Kushner J, Kim S, Hüttemann M, Polin L, Rabinowitz JD, Li J, Hou Z, Dann CE 3rd, Gangjee A, Matherly LH.

Mol Cancer Ther. 2019 Oct;18(10):1787-1799. doi: 10.1158/1535-7163.MCT-19-0037. Epub 2019 Jul 9.

PMID:
31289137
3.

Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma.

Dzinic SH, Mahdi Z, Bernardo MM, Vranic S, Beydoun H, Nahra N, Alijagic A, Harajli D, Pang A, Saliganan DM, Rahman AM, Skenderi F, Hasanbegovic B, Dyson G, Beydoun R, Sheng S.

PLoS One. 2019 Apr 19;14(4):e0215089. doi: 10.1371/journal.pone.0215089. eCollection 2019.

4.

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.

Li X, Su Y, Madlambayan G, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Ma J, Knight T, Wang G, Wang Y, Yang J, Taub JW, Lin H, Ge Y.

Haematologica. 2019 Nov;104(11):2225-2240. doi: 10.3324/haematol.2018.201343. Epub 2019 Feb 28.

5.

Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Sheng S, Margarida Bernardo M, Dzinic SH, Chen K, Heath EI, Sakr WA.

Cancer Metastasis Rev. 2018 Dec;37(4):655-663. doi: 10.1007/s10555-018-9767-4. Review.

6.

The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Bernardo MM, Dzinic SH, Matta MJ, Dean I, Saker L, Sheng S.

J Cell Biochem. 2017 Jul;118(7):1639-1647. doi: 10.1002/jcb.25969. Epub 2017 Mar 21. Review.

7.

The secretion and biological function of tumor suppressor maspin as an exosome cargo protein.

Dean I, Dzinic SH, Bernardo MM, Zou Y, Kimler V, Li X, Kaplun A, Granneman J, Mao G, Sheng S.

Oncotarget. 2017 Jan 31;8(5):8043-8056. doi: 10.18632/oncotarget.13302.

8.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DS, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Pang A, Harajli D, Sakr WA, Sheng S.

Cancer Res. 2017 Feb 15;77(4):886-896. doi: 10.1158/0008-5472.CAN-16-2219. Epub 2016 Dec 6.

9.

Tumor suppressor maspin as a modulator of host immune response to cancer.

Dzinic SH, Bernardo MM, Oliveira DS, Wahba M, Sakr W, Sheng S.

Bosn J Basic Med Sci. 2015 Oct 25;15(4):1-6. doi: 10.17305/bjbms.2015.783. Review.

10.

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI.

Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18.

11.

Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.

Bernardo MM, Kaplun A, Dzinic SH, Li X, Irish J, Mujagic A, Jakupovic B, Back JB, Van Buren E, Han X, Dean I, Chen YQ, Heath E, Sakr W, Sheng S.

Cancer Res. 2015 Sep 15;75(18):3970-9. doi: 10.1158/0008-5472.CAN-15-0234. Epub 2015 Jul 24.

12.

Maspin expression in prostate tumor elicits host anti-tumor immunity.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S.

Oncotarget. 2014 Nov 30;5(22):11225-36.

13.

Identification of an intrinsic determinant critical for maspin subcellular localization and function.

Dzinic SH, Kaplun A, Li X, Bernardo M, Meng Y, Dean I, Krass D, Stemmer P, Shin N, Lonardo F, Sheng S.

PLoS One. 2013 Nov 21;8(11):e74502. doi: 10.1371/journal.pone.0074502. eCollection 2013.

14.

Bacterial chemotaxis differences in Escherichia coli isolated from different hosts.

Dzinic SH, Luercio M, Ram JL.

Can J Microbiol. 2008 Dec;54(12):1043-52. doi: 10.1139/W08-105.

PMID:
19096459
15.

Variable length tandem repeat polyglutamine sequences in the flexible tether region of the Tsr chemotaxis receptor of Escherichia coli.

Dzinic SH, Shukla M, Mandija I, Ram TS, Ram JL.

Microbiology. 2008 Aug;154(Pt 8):2380-6. doi: 10.1099/mic.0.2008/016303-0.

PMID:
18667570

Supplemental Content

Loading ...
Support Center